Vect-Horus

Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain, and to tumors. Founded in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), formerly headed by Dr Michel Khrestchatisky, co-founder of the company. VECT-HORUS discovered, validated and optimized different families of vector molecules that target the LDL Receptor, Transferrin Receptor and undisclosed ones that allow drug targeted delivery to different organs. By combining pharmaceutical agents to its vectors, VECT-HORUS enables their transport across the BBB, which significantly impedes brain delivery of most drugs. Proof of concept of the technology was demonstrated in animal models for different vectorized molecules. Vect-Horus seeks to develop the broad potential of its proprietary VECTrans® technology platform through partnerships and licensing agreements.